Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Roivant Sciences (ROIV) EBIT (2020 - 2025)

Roivant Sciences (ROIV) has disclosed EBIT for 6 consecutive years, with -$339.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT fell 23.61% year-over-year to -$339.2 million, compared with a TTM value of -$1.2 billion through Dec 2025, down 127.32%, and an annual FY2025 reading of -$1.0 billion, changed N/A over the prior year.
  • EBIT was -$339.2 million for Q4 2025 at Roivant Sciences, down from -$306.2 million in the prior quarter.
  • Across five years, EBIT topped out at $5.1 billion in Q4 2023 and bottomed at -$1.1 billion in Q4 2021.
  • Average EBIT over 5 years is $8.2 million, with a median of -$282.3 million recorded in 2022.
  • The sharpest move saw EBIT crashed 451.36% in 2021, then skyrocketed 1456.19% in 2023.
  • Year by year, EBIT stood at -$1.1 billion in 2021, then skyrocketed by 65.15% to -$378.1 million in 2022, then surged by 1456.19% to $5.1 billion in 2023, then tumbled by 105.35% to -$274.4 million in 2024, then dropped by 23.61% to -$339.2 million in 2025.
  • Business Quant data shows EBIT for ROIV at -$339.2 million in Q4 2025, -$306.2 million in Q3 2025, and -$284.9 million in Q2 2025.